GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s share price traded down 4% on Wednesday . The stock traded as low as $114.21 and last traded at $116.56. 157,471 shares were traded during mid-day trading, a decline of 84% from the average session volume of 992,317 shares. The stock had previously closed at $121.47.
Wall Street Analyst Weigh In
WGS has been the subject of several research analyst reports. Wells Fargo & Company raised their price target on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Guggenheim reissued a "buy" rating and set a $115.00 price target (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Finally, Piper Sandler raised their price target on GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, September 11th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, GeneDx presently has a consensus rating of "Moderate Buy" and a consensus price target of $104.13.
Check Out Our Latest Report on GeneDx
GeneDx Trading Down 4.9%
The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. The business's 50-day simple moving average is $113.36 and its two-hundred day simple moving average is $93.23. The company has a market capitalization of $3.32 billion, a PE ratio of 2,300.20 and a beta of 2.03.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. On average, analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.
Insider Activity
In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $1,275,556.47. Following the completion of the sale, the chief executive officer owned 14,578 shares in the company, valued at $1,770,789.66. This represents a 41.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Casdin Capital, Llc sold 500,000 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the transaction, the director owned 3,007,164 shares in the company, valued at $363,566,127.60. This represents a 14.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 575,870 shares of company stock worth $69,280,301 in the last quarter. Insiders own 29.60% of the company's stock.
Institutional Investors Weigh In On GeneDx
Large investors have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its holdings in shares of GeneDx by 54.2% in the second quarter. Osaic Holdings Inc. now owns 8,835 shares of the company's stock valued at $816,000 after buying an additional 3,106 shares during the period. Thrivent Financial for Lutherans bought a new position in shares of GeneDx in the second quarter valued at about $267,000. Thompson Davis & CO. Inc. raised its position in shares of GeneDx by 22.5% in the second quarter. Thompson Davis & CO. Inc. now owns 17,330 shares of the company's stock valued at $1,600,000 after purchasing an additional 3,180 shares during the period. Cim LLC bought a new position in GeneDx during the second quarter worth about $440,000. Finally, Ashford Capital Management Inc. increased its position in GeneDx by 82.1% during the second quarter. Ashford Capital Management Inc. now owns 171,526 shares of the company's stock worth $15,834,000 after acquiring an additional 77,310 shares during the period. Institutional investors own 61.72% of the company's stock.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
